A groundbreaking clinical trial launching this year will test whether scientists can safely reverse aging at the cellular level in humans, potentially opening the door to treating age-related diseases like glaucoma and eventually rejuvenating entire organs. The trial builds on seven years of research showing that three genes can revert aging cells to a younger developmental state without turning them cancerous, a discovery that has attracted billions of dollars in investment from Silicon Valley's wealthiest entrepreneurs.

What Is Cellular Reprogramming and How Does It Work?

The technique at the heart of this trial is called partial reprogramming, and it works by introducing three genes into cells that essentially turn back their biological clock. In 2006, stem cell biologist Shinya Yamanaka discovered four proteins, now called Yamanaka factors, that could transform adult cells into induced pluripotent stem (iPS) cells capable of becoming any cell type in the body . But researchers wondered: what if you turned these genes on briefly, then turned them off before cells completely reset? The result could be cells that become younger without losing their identity.

Yuancheng Ryan Lu, a geneticist at the Whitehead Institute in Cambridge, Massachusetts, spent three years testing this idea on retinal nerve cells in mice. When he finally succeeded in introducing three of the Yamanaka factors into mouse eyes, he saw signs of new cell growth under the microscope. "I was so nervous," Lu recalled, remembering the moment his labmate confirmed the results. The discovery has now become the basis for a human clinical trial .

The approach removes one of the four original Yamanaka factors, a protein called c-Myc, because high levels of it can cause cancer. In a landmark study, researchers injected the three remaining factors into cells throughout the bodies of old mice. "We injected the mice and expected them to die, to be honest," said Noah Davidsohn, lead author on the study and chief scientific officer at Rejuvenate Bio, an aging-focused biotechnology company in San Diego, California . But months passed without tumors forming. Instead, several measures of health improved, and the mice lived longer than their unreprogrammed counterparts.

Why Are Investors Betting Billions on This Technology?

The potential of partial reprogramming has attracted unprecedented investment from Silicon Valley's tech elite. In 2020, Internet entrepreneur Yuri Milner gathered a select group of researchers in Los Altos Hills, California to discuss the future of the field. That meeting led to the founding of Altos Labs in 2022 with $3 billion in funding, setting a world record for biotech startup financing . Since then, other major investors have entered the space: Sam Altman, chief executive of OpenAI, invested in Retro Biosciences, which is working on partial reprogramming among other projects. Brian Armstrong, chief executive of cryptocurrency exchange Coinbase, helped found NewLimit, another partial reprogramming company .

The excitement stems from the possibility that this technique could eventually rejuvenate not just individual cells but entire organs. If successful in human eyes, the approach could restore eyesight to older adults with glaucoma, an age-related condition that damages the optic nerve. But the long-term vision is far more ambitious: someday, the same technique might be used to rejuvenate kidneys, livers, or even the brain itself .

What Are the Risks and Remaining Questions?

Despite the promise, significant risks remain. The central concern is that if cells are pushed too close to their stem-like state, they could lose their ability to function properly and potentially become cancerous. "When cells lose their identity, we know that comes with some forms of danger," noted Tamir Chandra, who studies aging at the Mayo Clinic in Rochester, Minnesota . Some researchers have expressed caution about leaving cells with unknown potential in the body. Daniel Ives, chief executive of Shift Bioscience in Cambridge, UK, offered a colorful analogy: "I'd argue that a dinosaur is not a good pet, even if you trained it very well" .

Researchers have experimented with different safety strategies to minimize these risks:

• Cyclic Gene Expression: Some teams cycle the Yamanaka genes on and off repeatedly rather than leaving them on continuously, reducing the time cells spend in a partially reprogrammed state.
• Transient Activation: Others turn the genes on only briefly, hoping they won't be active long enough to fully reprogram cells and cause them to lose their identity.
• Removing c-Myc: By excluding the cancer-promoting protein c-Myc and using only three of the four original Yamanaka factors, researchers have shown in mouse studies that tumors don't form even when the factors are introduced throughout the entire body.

While these approaches appeared safe in mice, doubts linger about translating them to humans. The upcoming clinical trial will be the first real test of whether partial reprogramming can safely reverse aging in human tissue .

How Does This Fit Into the Broader Aging Research Landscape?

Partial reprogramming represents one of several emerging approaches to extending human healthspan, the period spent in good health. Other technologies and therapies being explored include senolytics, which target and eliminate senescent cells that contribute to aging; gene therapy, which manipulates genetic material to address the root causes of aging; stem cell therapy, which uses regenerative cells to replace damaged tissue; and NAD+ boosters, which elevate levels of a crucial coenzyme involved in cellular processes .

Metformin, a common diabetes medication, has also shown promise in animal studies and some human evidence suggesting it may extend lifespan by improving the body's sensitivity to insulin . Resveratrol, found in grapes and red wine, has extended lifespan in yeast, worms, flies, and fish by activating sirtuins, proteins involved in cellular stress resistance and metabolic regulation . However, it's important to note that while these substances have displayed promise in preclinical research, their safety and efficacy in extending human lifespan are still under investigation .

What Should You Know About This Breakthrough?

The upcoming human trial represents a pivotal moment in longevity research. If successful, it could reshape the very concept of aging by demonstrating that old cells can safely be made young again. The trial will attempt to answer a question that has captivated researchers and investors alike: can cellular aging be reversed in humans without causing harm ?

The field is moving quickly. Life Biosciences, a biotechnology company in Boston, Massachusetts, is positioned to be among the first to test partial reprogramming in humans . The results of this trial could determine whether cellular rejuvenation becomes a viable treatment for age-related diseases or remains a promising but unproven concept. For now, the field is showing enough promise to draw the eye of some of the technology industry's wealthiest investors, suggesting that whether the trial succeeds or faces setbacks, the search for ways to reverse aging at the cellular level is far from over.